Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Thursday

Cadrenal Therapeutics (NASDAQ:CVKD) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

Cadrenal Therapeutics Trading Up 2.1%

Cadrenal Therapeutics stock opened at $8.30 on Thursday. The firm has a market capitalization of $19.42 million, a P/E ratio of -1.04 and a beta of 1.04. Cadrenal Therapeutics has a twelve month low of $4.91 and a twelve month high of $20.39. The stock’s fifty day simple moving average is $7.11 and its 200-day simple moving average is $10.37.

Insider Activity at Cadrenal Therapeutics

In related news, CFO Matthew K. Szot sold 9,933 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total value of $69,233.01. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 26.09% of the company’s stock.

Institutional Trading of Cadrenal Therapeutics

A number of institutional investors have recently bought and sold shares of CVKD. JPMorgan Chase & Co. acquired a new position in shares of Cadrenal Therapeutics during the 3rd quarter worth about $103,000. Geode Capital Management LLC raised its position in shares of Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the third quarter worth approximately $274,000. Finally, DRW Securities LLC acquired a new position in Cadrenal Therapeutics in the fourth quarter valued at approximately $171,000. 7.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $32.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.